Bevaris 400 mg/16 ml iv infusion is a medicine made by Aristopharma Ltd. Bevacizumab is used in the treatment of several cancers.
There are 12 brands of Bevacizumab listed in Bangladesh. 9 of them have a lower unit price than Bevaris. The lowest listed price is Bevastim 100 mg/4 ml IV Infusion at ৳ 13925.00 per unit.
What is Bevaris 400 mg/16 ml IV Infusion?
Made by Aristopharma Ltd., Bevaris is a iv infusion whose active ingredient is Bevacizumab. This interaction is linked to endothelial cell growth and the formation of new blood vessels. By interfering with this process, the medicine is used in the management of several types of cancer. Whether it suits you is a decision for your doctor.
Uses of Bevaris
Bevacizumab is used in the treatment of several cancers. It is used as part of a wider treatment plan chosen by the cancer specialist, often alongside other cancer medicines. It is often given together with chemotherapy as part of a wider treatment plan. Ask your doctor how it fits into your own treatment.
How to use Bevaris
It is not intended for use at home. Swallow the iv infusion with water unless your doctor or pharmacist advises otherwise. Do not change or stop the treatment plan on your own; ask the cancer doctor if you have questions about how it is being given. The doctor decides the dose, the schedule and how long treatment continues, based on the cancer being treated, the person's condition and any other medicines being used.
Side effects of Bevaris
Dry or watery eyes, dry or flaky skin, hair loss, changes in taste, jaw pain, swelling or numbness, loose teeth and gum infection have also been reported. Reported effects include dry mouth, cough, voice changes, loss of appetite, diarrhoea, nausea, vomiting, constipation, mouth sores, headache, back pain and cold-like symptoms such as a stuffy nose, sneezing or sore throat. Some people may experience side effects. Tell your doctor or nurse about any side effect that worries you or does not settle.
Safety and precautions
The risk of certain blood vessel problems during treatment is increased in people with a history of arterial thromboembolism, diabetes, or older age; discuss your history with your doctor. Always ask your doctor or pharmacist about any concerns. It is pregnancy category C, and there are no adequate or well-controlled studies in pregnant women; it is not known whether it passes into human milk. Ask your doctor first if any of these apply to you.
Frequently asked questions
What is Bevaris used for?
Bevacizumab is used in the treatment of several cancers. It is used as part of a wider treatment plan chosen by the cancer specialist, often alongside other cancer medicines.
How should I take Bevaris?
It is not intended for use at home. Swallow the iv infusion with water unless your doctor or pharmacist advises otherwise.
What are the side effects of Bevaris?
Dry or watery eyes, dry or flaky skin, hair loss, changes in taste, jaw pain, swelling or numbness, loose teeth and gum infection have also been reported. Reported effects include dry mouth, cough, voice changes, loss of appetite, diarrhoea, nausea, vomiting, constipation, mouth sores, headache, back pain and cold-like symptoms such as a stuffy nose, sneezing or sore throat.
Persistent, Recurrent, or Metastatic Carcinoma of the Cervix
Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Pharmacology
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.
Dosage & Administration
Metastatic Colorectal Cancer (mCRC): The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy.
Administer 5 mg/kg when used in combination with bolus-IFL.
Administer 10 mg/kg when used in combination with FOLFOX4.
Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Bevacizumab-containing regimen.
Non-Squamous Non-Small Cell Lung Cancer (NSCLC): The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel.
Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks.
Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa.
Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.
Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10mg/ kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks).
Interaction
A drug interaction study was performed in which irinotecan was administered as part of the FOLFIRI regimen with or without Bevacizumab. The results demonstrated no significant effect of Bevacizumab on the pharmacokinetics of irinotecan or its active metabolite SN38.
In a randomized study in 99 patients with NSCLC, based on limited data, there did not appear to be a difference in the mean exposure of either carboplatin or paclitaxel when each was administered alone or in combination with Bevacizumab. However, 3 of the 8 patients receiving Bevacizumab plus paclitaxel/carboplatin had substantially lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at Day 0, while patients receiving paclitaxel/carboplatin without Bevacizumab had a greater paclitaxel exposure at Day 63 than at Day 0.
Contraindications
There are no contraindications listed in the manufacturer’s labeling.
Side Effects
dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection.
Pregnancy & Lactation
Pregnancy Category C. There are no adequate or well controlled studies of bevacizumab in pregnant women. It is not known whether Avastin is secreted in human milk.
Precautions & Warnings
Arterial Thromboembolic Events. Among patients receiving Bevacizumab in combination with chemotherapy, the risk of developing ATE during therapy was increased in patients with a history of arterial thromboembolism, diabetes, or age greater than 65
Overdose Effects
The highest dose tested in humans (20 mg/kg IV) was associated with headache in nine of 16 patients and with severe headache in three of 16 patients.
Storage Conditions
Bevacizumab vials are stable at 2 to 8° C. Bevacizumab vials should be protected from light. Do not freeze or shake. Diluted Bevacizumab solutions may be stored at 2 to 8° C for up to 8 hours. Store in the original carton until time of use. No incompatibilities between Bevacizumab and polyvinylchloride or polyolefin bags have been observed.
Alternative brands of Bevacizumab
Other brands with the same generic name, cheapest first.